Understanding drug ADME’s mechanisms, rates, and routes is essential in discovery and development. Whether the focus is on lead optimization, candidate identification or profiling, or preparing for Investigational New Drug (IND) or New Drug Application (NDA) regulatory submissions, Pharmaron’s integrated in vitro and in vivo ADME services can deliver extensive support.

Enabling rapid decision-making

Pharmaron works closely with our clients as a fully integrated partner, guiding them through the entire process and providing timely, high-quality data while simplifying and expediting program decisions.

• Our cross-functional team of experienced DMPK scientists and leaders covers all aspects of DMPK, from drug discovery to regulatory submission and everything in between.
• Our consultancy-based approach provides strategic and experimental guidance and continuity.
• Our facilities support non-GLP, GLP, and GCP-compliant bioanalytical services, minimizing the need for technology transfers.
• Data are delivered to meet all requirements, spanning rapid data upload during DMTA cycles to regulatory reports.
• Pharmaron offers a one-stop shop for continuous solutions, reducing the cost and complexity of sourcing solutions from multiple specialist vendors.